FRIDAY, July 6, 2018 -- Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma, according to a study published in the July 5 issue of the New England...
Original Article: Cabozantinib Improves Survival in Advanced Hepatocellular Cancer